Literature DB >> 6879511

Calibration of reference thromboplastins and standardisation of the prothrombin time ratio.

T B Kirkwood.   

Abstract

Thromboplastins vary in their sensitivity to the haemostatic defect induced by oral anticoagulants. To provide a means of standardising prothrombin time tests, the World Health Organization adopted in 1977 a scheme for calibrating thromboplastins in terms of an International Reference Preparation. Unfortunately, the model on which this scheme was based does not always hold. A revised calibration model has therefore been developed and this has been tested in a recent collaborative study. The revised model, which retains fundamentally the same principle for standardising prothrombin time tests, has proved suitable for calibrating thromboplastins of different species and types and, moreover, has certain statistical advantages over its predecessor. In September 1982, the WHO Expert Committee on Biological Standardization adopted the revised model. This paper explains the nature and rationale of this change and considers its practical implications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6879511

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  31 in total

Review 1.  Therapeutic ranges for oral anticoagulation in different thromboembolic disorders.

Authors:  L Poller
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Guidelines on oral anticoagulation: second edition. British Society for Haematology. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

4.  Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Teddy Kosoglou; Yali Zhu; Fengjuan Xuan; Laura Black; Amy O Johnson-Levonas; Monika Martinho; Paul Statkevich; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

5.  Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Rajesh Krishna; Daria Stypinski; Melissa Ali; Amit Garg; Josee Cote; Andrea Maes; Bruce Degroot; Yang Liu; Susie Li; Sandra M Connolly; John A Wagner; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

6.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

7.  ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. International Committee for Standardization in Haematology/International Committee on Thrombosis and Haemostasis.

Authors: 
Journal:  Blut       Date:  1985-03

8.  Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation.

Authors:  Aida Kulo; Nedzad Mulabegović; Jasna Kusturica; Hasija Hadzić; Lejla Burnazović-Ristić; Maida Rakanović-Todić; Amila Mehmedović; Orhan Lepara
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

Review 9.  Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Authors:  Thomas P Moyer; Dennis J O'Kane; Linnea M Baudhuin; Carmen L Wiley; Alexandre Fortini; Pamela K Fisher; Denise M Dupras; Rajeev Chaudhry; Prabin Thapa; Alan R Zinsmeister; John A Heit
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 10.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.